Breast Cancer Trials (BCT) is a world leading clinical trials research organisation, dedicated to finding new and better treatments and prevention strategies for people affected by this disease.
Our research program involves multicentre national and international clinical trials and brings together more than 820 researchers in 109 institutions throughout Australia and New Zealand. BCT has contributed to almost 1,200 peer reviewed publications and more than 16,300 women have participated in our breast cancer clinical trials.
The theme for the 2022 Annual Scientific Meeting (ASM) is breast cancer in young women, with a number of key presentations on this important topic. The ASM will also host a number of internationally renowned guest speakers including key BCT researchers. Delegates include leading Australian and New Zealand medical practitioners and clinicians, and clinical trials management personnel.
The full and extensive program will include two days of scientific sessions covering timely reviews of breast cancer clinical trials, discussion of new protocols, future clinical trials research and other research developments.
As a result of COVID-19, we were unable to host a meeting in 2020 and held our first virtual ASM in 2021. In 2022, we look forward to an in-person meeting, offering the opportunity for us all to re-connect in Melbourne, Victoria.
The Breast Cancer Trials ASM is not open to the general public to attend
For up to date information on COVID-19 in Victoria, including travel requirements, visit: https://www.coronavirus.vic.gov.au/
Attracting leading health professionals involved in the conduct of breast cancer clinical trials throughout Australia and New Zealand, the Breast Cancer Trials Annual Scientific Meeting is an important event to stay up-to-date on research and to network with colleagues.
Please note that this is a closed meeting.
Please note that the Trials Coordination Forum is primarily for Trial/Study Coordinators; not suitable for Pharmaceutical representatives.
A New Concept Workshop will be held at the Annual Scientific Meeting (ASM) to provide an opportunity for Breast Cancer Trials (BCT) members and non-members to present new research ideas.
The workshop will be held at The Langham, Melbourne, and will involve a presentation of selected concepts, followed by discussion and feedback from the audience.
Moderated by Annabel Crabb.
Members of the public and ASM delegates are invited to attend our annual Q&A Event, to hear the latest news on breast cancer research and clinical trials from leading Australian and international researchers.
Recent Developments in Management of HR+ve Breast Cancer.
Download the Symposium Agenda: Lilly Breakfast Symposium Agenda
Sponsored by:
Personalising Therapy and Implications for Radiation Therapy.
Download the Symposium Agenda: GenesisCare Breakfast Symposium Agenda
Sponsored by:
View Scientific Sessions Program
Please note, this meeting is for BCT members only.
Conference Dinner Sponsored by:
The Role of MDT in the Management of Early Triple-Negative Breast Cancer.
Download the Symposium Agenda: MSD Breakfast Symposium Agenda
Sponsored by:
Sequencing Treatment in Metastatic TNBC.
Download the Symposium Agenda: Gilead Lunch Symposium Agenda
Sponsored by:
Professor of Medicine, Harvard Medical School, & Vice Chair of Medical Oncology, Dana-Faber Cancer Institute
Ann Partridge is a Professor of Medicine at Harvard Medical School, and Vice Chair of Medical Oncology at Dana-Farber Cancer Institute, where she also serves as Director of the Adult Survivorship Program and leads the Program for Young Women with Breast Cancer.
As a medical oncologist and clinical researcher, she has sought to improve the care and outcomes of patients with cancer by conducting research, and by developing innovative clinical programming. Professor Partridge serves in leadership roles nationally and internationally including as co-chair of the Breast Committee of the Alliance for Clinical Trials in Oncology and co-chair of the biennial ESMO-ESO sponsored Breast Cancer in Young Women Conference.
She also served as Chair of the Center for Disease Control and Prevention (CDC) Advisory Committee on Breast Cancer in Young Women from 2010-17. She has received prior awards and grants including a Champions of Change award from the White House, an ASCO Improving Cancer Care Grant, the CDC Carol Friedman Award, the American Association for Cancer Research (AACR) Outstanding Investigator Award for Breast Cancer, and the Ellen L. Stovall Award in Cancer Survivorship from ASCO, and the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School.
After graduating from Georgetown University, Professor Partridge received her medical degree from Cornell University Medical College, pursued an internal medicine residency at the Hospital for the University of Pennsylvania, and completed Medical Oncology and Hematology fellowship at Dana-Farber/Partners Cancer Care. She earned a Master of Public Health degree at the Harvard School of Public Health.
Vice Director & Chief of Breast Oncology, Aichi Cancer Center Hospital, Clinical Professor at Nagoya University Medical School
Hiroji Iwata is Vice Director and Chief of Breast Oncology at Aichi Cancer Center Hospital, He is also a Clinical Professor at Nagoya City University Medical School.
He is an author of over 200 publications on a wide range of subjects in the treatment of early stage and metastatic breast cancer. He is a director of Breast Cancer Study Group in Japan Clinical Oncology Group (JCOG), a steering committee member in many global clinical trials.
Clinician-Scientist, Peter MacCallum Cancer Centre, & Chair-Elect of the Society of Clinical Oncology Education Committee
Shom Goel is a clinician-scientist at the University of Melbourne and Peter MacCallum Cancer Centre. Having spent ten years in Boston, where he completed his doctoral and postdoctoral research, Dr Goel returned to Australia in 2019. In addition to maintaining a clinical practice as an oncologist, he also leads a research group, which positions itself at the intersection of cell cycle biology, epigenetics, and tumour immunology in breast cancer.
They have developed several new transgenic mouse models of breast cancer, which have proven valuable for uncovering new mechanisms of drug activity and resistance, and their work has been published in high-impact journals including Nature, Cancer Cell and Nature Cancer. He serves as either Global PI or Translational PI for four randomised clinical trials in breast cancer and was recently appointed Chair-Elect of the American Society of Clinical Oncology Education Committee.
Dr Goel is also a recent awardee of a prestigious Snow Fellowship which will accelerate his laboratory’s work from 2022 – 2030.
Medical Oncologist & Advisor with Breast Cancer Trials, consulting across the Hunter Region in NSW Australia
Nicholas Zdenkowski is a Medical Oncologist and Medical Advisor with Breast Cancer Trials. He sits on the BCT Scientific Advisory Committee and the PALLAS trial Steering Committee. He works on a broad range of breast cancer research, including shared decision-making, clinical trials and patient reported outcomes, particularly around neoadjuvant systemic therapy. His PhD project resulted in the development of a decision aid for patients considering neoadjuvant systemic therapy for breast cancer. He has published widely, from patient reported outcomes, systematic reviews and clinical trial outcomes. He consults at Lake Macquarie Private Hospital and Maitland Private Hospital in the Hunter Region in NSW Australia.
Associate Professor in Clinical Psychology, consulting in the Breast Service & Familial Cancer Centre at Royal Melbourne Hospital
Lesley Stafford is a clinical psychologist with more than 15 years of research and clinical expertise in psycho-oncology and women’s health, with a specific interest in women with or at risk of breast cancer. She consults in the Breast Service and Familial Cancer Centre at the Royal Melbourne Hospital as well as in private practice and is an Associate Professor at the University of Melbourne. Lesley has published 65 papers in peer-reviewed journals and contributed several invited chapters to academic textbooks. Areas of interest include parenting with cancer, decision-making in the context of risk-reducing interventions, psychological implications of treatment de-escalation and sequence, and psychosocial aspects of advances in genetic testing.
Senior Principal Research Fellow and co-leader of the Strategic program in Dynamic Cancer Ecosystems
Associate Professor Alex Swarbrick is a Senior Principal Research Fellow and co-leader of the Strategic program in Dynamic Cancer Ecosystems at the Garvan Institute of Medical Research; a conjoint associate professor at UNSW Sydney and an NHMRC Senior Research Fellow. Alex completed his PhD at UNSW, followed by a postdoctoral fellowship with J. Michael Bishop at UCSF. His lab applies cellular genomics to human solid cancers to gain systems-level insights into disease aetiology and the development of novel treatment strategies.
Professor of Surgery and Radiology at the University of California, San Francisco (UCSF) and director of the UCSF Breast Care Clinic
Laura Esserman is Professor of Surgery and Radiology at the University of California, San Francisco (UCSF) and director of the UCSF Breast Care Clinic.
Her work in breast cancer spans the spectrum from basic science to public policy issues, and the impact of both on the delivery of clinical care. Professor Esserman is recognized as a thought leader in cancer screening and over-diagnosis, as well as innovative clinical trial design.
She led the creation of the University of California-wide Athena Breast Health Network, a learning system designed to integrate clinical care and research as it follows 150,000 women from screening through treatment and outcomes. The Athena Network launched the PCORI-funded Wisdom Study, which tests a personalized approach to breast cancer screening in 100,000 women.
She is also a leader of the innovative I-SPY TRIAL model, designed to accelerate the identification and approval of effective new agents for women with high risk breast cancers. In 2020 she got FDA approval for an I-SPY Covid trial, designed to rapidly screen and confirm high impact treatments to reduce mortality and time on ventilators.
Head of the Translational Breast Cancer Genomics & Therapeutics Laboratory, Peter MacCallum Cancer Centre
Professor Sherene Loi is a Medical Oncologist specialising in breast cancer treatment as well as a clinician scientist with expertise in genomics, immunology and drug development. She is the Head of the Translational Breast Cancer Genomics and Therapeutics laboratory at the Peter MacCallum Cancer Centre, Melbourne, as well as Consultant Medical Oncologist in the Breast Service and head of the Breast Cancer Clinical Trials Unit.
As a result of her research, Professor Loi has led a number of international breast cancer clinical trials in immunotherapy. She has published over 240 peer-reviewed research articles with a lifetime H index of 82 and recent work has been highly influential with 34,058 total citations and 25,117 (74%) within the past 5 years (Google Scholar).
Professor Loi Co-Chairs the Scientific Executive Committee and the Translational Working Group of the International Breast Cancer Study Group (IBCSG) based in Bern, Switzerland which conducts academic global breast cancer clinical trials in over 16 countries. She is the current holder of the Inaugural National Breast Cancer Foundation (NBCF) of Australia Endowed Chair and is a research fellow of the Breast Cancer Research Foundation (BCRF), New York.
Professor Loi was elected to the Breast Cancer Trials (BCT) Board of Directors in July 2020. She is a member of the BCT Scientific Advisory Committee and the Nominations Committee.
Medical Oncologist at Wellington Hospital, New Zealand and Clinical Senior Lecturer at the University of Otago, School of Medicine
David is a medical oncologist practicing at Wellington Hospital, New Zealand, and also undertakes private practice in Bowen Icon Cancer Centre, Wellington. He has a special interest in breast cancer, with a particular focus on cancer care in the elderly. He is a Clinical Senior Lecturer at the University of Otago, School of Medicine and is involved in research as an investigator in clinical trials at Wellington Hospital. He is also an active member of the American Society of Clinical Oncology, the European Society of Medical of Oncology and the Society of Geriatric Oncology.
Medical Oncologist at the Peter MacCallum Cancer Centre, Melbourne, and PhD candidate at the University of Melbourne
Wanda (Wanyuan) Cui is a medical oncologist at the Peter MacCallum Cancer Centre, Melbourne, and PhD candidate at the University of Melbourne investigating treatment related ovarian failure in breast cancer. She has a special interest in cancer prevention and oncofertility.
Consultant Medical Oncologist at the Chris O'Brien Lifehouse, & Clinical Research Associate at the Garvan Institute
Sanjeev Kumar is a Consultant Medical Oncologist at the Chris O'Brien Lifehouse (RPA), a Staff Specialist at Westmead Hospital, and a Clinical Research Associate at the Garvan Institute. He grew up in country NSW, completed undergraduate medical studies at UNSW, and trained as a Medical Oncologist in Central Sydney and in the United Kingdom.
He embarked on a Cancer Drug Development fellowship with the University of Cambridge UK in 2015 and was subsequently awarded a University of Cambridge and Cancer Research UK scholarship in 2016 to complete a cancer molecular biology PhD at the Cancer Research UK Cambridge Institute, with a focus on Oestrogen receptor-positive breast cancer.
Sanjeev returned to Australia in 2019 to continue his clinical and academic focus on breast cancer. He has a keen interest in the education of trainees, public engagement, and clinical trials.
Professor and Head of the Gene Regulation and Translational Medicine Group at QIMR Berghofer in Queensland
Sudha Rao has extensive experience in transcriptional biology and genomic technologies that spans both pharmaceutical and academic settings. The primary focus of Professor Rao’s research group has been to unravel complex epigenetic-signatures in the immune system, as well as to understand the deregulatory mechanisms operating in cancer settings as well as the role of epigenetic regulation in viral infection. She has obtained her BSC (Hons.) degree at Keele University, UK. PhD from the University of London, Kings College in 2000. During this period, she joined a team of scientists at Rhone Poulenc/Sanofi Pharma, both in UK and France. During this time, she was part of one of the first groups world-wide to establish the clinical genomics platform for therapeutics in the UK. She has developed close partnerships with global technology companies and established novel liquid biopsy clinical platforms, first of its kind in Asia, for non-invasive tracking of blood samples from cancer patients. She has attracted highly competitive NHMRC, ARC and commercial funding to advance her cancer work. Sudha’s work has yielded national and international patents for both novel diagnostics and therapeutics in the emerging arena of immune-oncology as well as novel therapeutics and diagnostics for viral infections. Professor Rao has a 20-year track record in translational epigenetics in both academia and industry, where she has led drug development and biomarker discovery projects to take novel therapeutics from bench to clinic. This is evidenced by publications in highly ranked journals; continuing funding as lead CI on multiple NHRMC and ARC grants and substantive commercial funding (~10M last 5 years); active outreach, raising substantial philanthropic funds for basic and clinical research; lead inventor on 37 patents; several worldwide patents. Professor Rao has supervised as primary supervisor for 10 PhDs and 20 honours/masters and has mentored on ECR programs both in the teaching and research contexts. During her time in industry, she worked in drug discovery and clinical trials, developing drugs to tackle respiratory diseases, COPD, and asthma, paving the way for her current clinical epigenetics-based therapeutics and biomarker program and industrial partnerships. Her work has led to translational outcomes, an international patent portfolio, and EpiAxis Therapeutics, of which she is founder, director, and CSO (until commencing at QIMRB, 2020), with a successfully completed clinical trial; licencing partnership with Pharma to take novel immunotherapy approaches to the clinic.
Professor of Breast Cancer Clinical Oncology and Deputy Head of Department of Oncology, University of Cambridge
Charlotte Coles is Professor of Breast Cancer Clinical Oncology and Deputy Head of Department of Oncology, University of Cambridge. Her research aims are to provide cancer patients with the best chance of cure with least side effects by personalising radiation techniques. Charlotte is passionate about developing, delivering and implementing patient-centred research through team science and nurturing the next generation of researchers.
Professor Coles graduated from University of Leicester Medical School and then trained in Medicine and Clinical Oncology. She undertook a PhD studentship in breast radiotherapy (RT) and led the Cambridge Breast intensity modulated RT (IMRT) trial as a trainee. For 12 years, Charlotte worked as clinical oncology NHS consultant whilst carrying out national clinical trial research.
She was appointed as Reader, University of Cambridge in 2017 and was awarded a National Institute of Health Research (NIHR) Research Professorship in 2019 for her risk-adapted breast RT research programme. Professor Coles successfully led the Cancer Research UK (CRUK) Radiation Research Centre of Excellence award at Cambridge to develop a translational research pipeline from basic radiation research through to clinical trials, with a focus on DNA damage response and genetic approaches to define drug-RT combinations.
She is Chief Investigator for 5 multicentre clinical trials: IMPORT LOW & HIGH, PRIMETIME, NEO-RT and PARABLE. Professor Coles chaired the NCRI Early Disease Breast Cancer sub-group and is a member of the NIHR Health Technology Assessment Committee and the CRUK Clinical Research Committee. International roles include scientific tracks/faculty for SABCS, ESMO, EBCC and ESTRO.
She was Editor-in-Chief of Clinical Oncology journal from 2015-21 and stepped down in 2021 to lead the Lancet Commission for Breast Cancer.
Associate Professor in Clinical Psychology & Consulting Clinical Psychologist in Medical Oncology at Flinders Medical Centre
Lisa Beatty is an Associate Professor in Clinical Psychology at Flinders University and a visiting Consulting Clinical Psychologist in Medical Oncology at Flinders Medical Centre. She has over 17 years of research and clinical expertise in the field of psycho-oncology, and has attracted over $2M in competitive project grant and salary funding. Lisa has published over 50 journal articles/book chapters/reviews, and has received five awards in recognition of her work, including a 2017 South Australian Young Tall Poppy Science Award.
Clinical Lead in Breast Medical Oncology, Peter MacCallum Cancer Centre, Melbourne & Scientific Advisory Committee member
Professor Prue Francis is Clinical Lead Breast Medical Oncology, Peter MacCallum Cancer Centre, Melbourne
Prue is a medical oncologist breast cancer clinician researcher. She received her medical degree from the University of Melbourne and completed Medical Oncology training at Memorial Sloan-Kettering Cancer Center in New York. She returned to Australia in 1994 as a Consultant Medical Oncologist at Peter MacCallum. She is a Visiting Medical Oncologist at St Vincent’s Hospital, Melbourne.
Prue is a member of the Scientific Advisory Committee of Breast Cancer Trials (BCT).
She is a member of the St. Gallen International Expert Consensus Panel on the Primary Therapy of Early Breast Cancer, the Advanced Breast Cancer (ABC) International Consensus Panel, and the Steering Committee for the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).
Oncologist and Sub-Specialist in breast and lung cancer at the Peter MacCallum Moorabbin campus (Monash Cancer Centre)
Dr Steven David is a radiation oncologist who graduated from the University of Western Australia before completing his specialist training at the Peter MacCallum Cancer Centre in Melbourne. Subsequently, he took up a position as a sub-specialist in breast and lung cancer at the Peter MacCallum Moorabbin campus (Monash Cancer Centre). Steven has been the lead investigator in a number of local clinical trials and has been involved in recruitment to a number of international trials. His current areas of research include development and implementation of a Deep Inspiration Breath Hold Technique to reduce radiation to the heart for patients with left sided breast cancer and the use of high dose precision radiation (SABR) for the treatment of patients with metastatic disease.
Medical Oncologist at the Austin Hospital, Melbourne, & Clinician-Scientist at the Olivia Newton-John Cancer Research Institute
Belinda Yeo is jointly appointed to the Austin Hospital in Melbourne, Australia, as a Medical Oncologist and to the Olivia Newton-John Cancer Research Institute as a Clinician Scientist with a specific interest in breast cancer. She trained in Sydney before joining the Breast Unit at The Royal Marsden Hospital, London as a Clinical and Research Fellow. She completed a Master’s Degree at The University of London and The Institute of Cancer Research in novel genomic and non-molecular breast cancer risk assays. She is co-lead of the VCCC Research and Education Stream for Breast Cancer, she is a clinical trial investigator and continues her translational research investigating improving personalization and minimising toxicities for patients with breast cancer.
Head of the Women’s Hospital Breast Imaging Service, & Associate at the University of Melbourne Radiology Department
Dr Allison Rose obtained her medical degree from The University of Melbourne. She underwent general radiology training at The Royal Melbourne Hospital, attaining M.Med. FRANZCR in 1988. She was appointed as a consultant radiologist at The Royal Melbourne Hospital in 1989 after a period in London working to gain experience in women’s imaging. She was one of the original radiologists with the Victorian Pilot Program for the Early Detection of Breast Cancer from 1989 under the auspice of The Royal Melbourne Hospital, and became Director of Northwestern BreastScreen in 1999.
In 2009 she became Head of Breast Imaging for the combined Royal Melbourne & the Womens Hospital Breast Service & in this role she has led the team to develop fully integrated comprehensive breast imaging across diagnostic and screening services. 2001-2006 she was Deputy Director of the Radiology Department at The Royal Melbourne Hospital and was the main champion for implementation of enterprise wide PACS. She was instrumental in establishing Breast MRI & MRI guided biopsy for the service and more recently, CEM. She is a keen educator having launched Melbourne Breast MRI Intensive Courses in 2011.
Her research interests include de-escalation of breast cancer treatment, risk adjusted screening for breast cancer and the role of contrast based imaging in BreastScreen assessment, cancer staging and surveillance.
Professor of Medicine in the Division of Hematology & Oncology at the University of California, San Francisco
Hope S. Rugo, MD, is Professor of Medicine in the Division of Hematology and Oncology at the University of California San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center, where she is also the Director, Breast Oncology and Clinical Trials Education. In addition, Dr. Rugo is a member of the ALLIANCE Breast Committee and the Translational Breast Cancer Research Consortium, is the UCSF representative to the National Comprehensive Cancer Network Guidelines Committee, serves on several committees for the American Society of Clinical Oncology, and is a voting member of the Advanced Breast Cancer Guidelines Consortium.
With a summa cum laude undergraduate degree from Tufts University, Dr. Rugo received her medical degree from the University of Pennsylvania School of Medicine. She then completed both a residency in internal medicine and fellowship in hematology and oncology at UCSF. Dr. Rugo then capped off her formal education with the completion of a 2-year postdoctoral fellowship in immunology at Stanford University.
An active researcher, Dr. Rugo has published many peer-reviewed papers and given presentations on a variety of breast cancer and supportive care-related topics. She is also an investigator and chair of the Safety Committee for the national multicenter ISPY2 trial, and is the principal investigator of a number of clinical trials. Her research interests include novel therapies for advanced breast cancer, immune modulation to restore chemotherapy sensitivity, evaluation of circulating cells as novel markers of response and resistance to therapy, neoadjuvant therapy, and supportive care. Dr. Rugo is the recipient of a Komen Promise Award, receives funding from the Breast Cancer Research Foundation, the 2010 recipient of the Cancer Care Physician of the Year Award, and is a fellow of the American Society of Clinical Oncology. She is on the Steering Committees for several international clinical trials.
Head of the Breast Cancer Research Group in the Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide
Theresa Hickey received her PhD in Medicine at the University of Adelaide in 2006 and is currently a National Breast Cancer Foundation Fellow and Head of the Breast Cancer Research Group in the Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide, South Australia. Her broad research interest is androgen receptor activity in female tissues, with a focussed interest in androgen receptor signalling in relation to normal breast biology and breast cancer. Associate Professor Hickey has also investigated androgen receptor signalling in polycystic ovary syndrome and in prostate and ovarian cancers. Her work published in Nature Medicine in 2021 resolved a clinical controversy about the role of androgen receptors in estrogen receptor positive breast cancers and provided strong evidence for use of an androgen receptor agonist strategy for treatment of early and advanced disease states. This work underpinned initiation of the Phase 3 ARTEST trial (NCT 04869943; recruiting) to test efficacy of the selective androgen receptor modulator Enobosarm in women with metastatic estrogen receptor positive breast cancer.
Consultant Breast Surgeon and Associate Professor of the University of Sydney with the Royal Prince Alfred Academic Institute
Sanjay Warrier is a Consultant Breast Surgeon who is also trained in Oncoplastic Techniques. He is a current Council member for Breast Surgeons of Australia New Zealand (BreastSurgANZ) and is the immediate past President (May 2019 until May 2020). His rooms are located at Chris O’Brien Lifehouse and Macquarie Street, Sydney. He is also a Visiting Medical Officer at BreastScreen NSW.
He is an Associate Professor of the University of Sydney with the Royal Prince Alfred Academic Institute. He is lead researcher at the Institute with goals of developing and creating a culture of academia within the Breast Department.
Associate Professor Warrier completed his undergraduate medical training at the University of New South Wales in 2002. Following this, he undertook general surgical training at the Prince of Wales Hospital Network where he had a broad exposure to oncology surgery. His post fellowship training has been extensive with three and a half years of training in breast surgery. As part of this, he spent one and a half years at the Prince of Wales Hospital and Royal Hospital for Women within the Breast Surgical Oncology Unit. He was then based for two years at the Oncoplastic Breast Unit at Royal Prince Alfred Hospital, consolidating surgical techniques in both an oncological and reconstructive setting.
He is a committed researcher in breast cancer medicine and surgery and within the last 12 months has presented at eight national and international conferences including the San Antonio Breast Symposium and the American Society of Clinical Oncology (ASCO). In 2013, his work on Hedgehog signaling, in collaboration with the Garvan Institute, won the Patron's Prize at the Royal Prince Alfred Hospital for best scientific research. He has also published many papers and co-authored articles in peer reviewed journals and magazines.
Associate Professor Warrier is passionate about patient care, teaching and research and is the current Chairman of Post-Fellowship Training for BreastSurgANZ, a role that involves training future breast surgeons in Australia and New Zealand. as well as the current Site Director of Surgical Training at Royal Prince Alfred Hospital.
Professor of Surgery at The University of Melbourne, and Director of Research at Breast Cancer Trials
Professor Bruce Mann is Professor of Surgery at The University of Melbourne, Director of the Breast Tumour Stream at the Victorian Comprehensive Cancer Centre and is Director of Research at Breast Cancer Trials.
He has facilitated clinical and translational research into all aspects of breast cancer via the development and maintenance of extensive clinical data collection. His research interests focus on tailored screening and treatment for early breast cancer. He was PI on Australia’s first decision impact study of Oncotype Dx, PI on a validation study of the DCISionRT assay for DCIS, national PI of the POSNOC study of axillary treatment for those with positive sentinel nodes, and is an instigator and principal investigator of the PROSPECT trial.
Associate Professor of Medicine at the University of Sydney & Director of Medical Oncology at the Crown Princess Mary Cancer Centre
Epidemiologist specialising in Breast Screening and Head of the Breast Cancer Policy & Evaluation Stream at the Daffodil Centre
A/Prof Carolyn Nickson is an epidemiologist specialising in breast cancer screening. She heads the Breast Cancer Policy and Evaluation Stream at The Daffodil Centre, a joint venture between the University of Sydney and Cancer Council NSW. She leads the Australian Government funded project ‘ROSA’ which is exploring options for risk-based breast cancer screening in Australia, and heads a team of researchers working on national and international epidemiological, clinical, modelling and implementation studies aiming to reduce the burden of breast cancer.
This award recognises a member of BCT who has made an outstanding contribution to the BCT’s clinical trials research program.
This award was established to encourage potential academic Breast Cancer Surgeons to become involved in clinical trials research.
This award recognises a Translational Researcher and their achievements and contributions to improved patient outcomes and is open to BCT members and non-members worldwide.
These grants recognise Full Members of BCT who are unable to access institutional or other funding to attend the Annual Scientific Meeting.
The ASM Secretariat is responsible for conference registration only and delegates are responsible for their accommodation. You can book your accommodation at The Langham, Melbourne here.
Alternatively, there are several hotels within walking distance to The Langham Melbourne.
Members of the public and ASM delegates are invited to attend our annual Q&A Event, to hear the latest news on breast cancer research and clinical trials from leading Australian and international researchers.
This free event will be held at Federation Square on the evening of 27 July, 2022.
Further details and registration information will be available closer to the date.